

# Janet Turk Wittes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5566591/publications.pdf>

Version: 2024-02-01

28  
papers

2,729  
citations

471509

17  
h-index

580821

25  
g-index

35  
all docs

35  
docs citations

35  
times ranked

3224  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 -mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , 2017, 390, 849-860.	13.7	1,250
2	The role of internal pilot studies in increasing the efficiency of clinical trials. <i>Statistics in Medicine</i> , 1990, 9, 65-72.	1.6	397
3	Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 257.	7.4	168
4	Internal pilot studies II: comparison of various procedures. , 1999, 18, 3493-3509.		115
5	Long-term survival of participants in the <scp>CENTAUR</scp> trial of sodium phenylbutyrate&#x2013;taurursodiol in <scp>amyotrophic lateral sclerosis</scp>. <i>Muscle and Nerve</i> , 2021, 63, 31-39.	2.2	115
6	Internal pilot studies I: type I error rate of the naïvet-test. , 1999, 18, 3481-3491.		77
7	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
8	Data monitoring committees: Promoting best practices to address emerging challenges. <i>Clinical Trials</i> , 2017, 14, 115-123.	1.6	61
9	Behind closed doors: The data monitoring board in randomized clinical trials. <i>Statistics in Medicine</i> , 1993, 12, 419-424.	1.6	59
10	Toward protecting the safety of participants in clinical trials. <i>Contemporary Clinical Trials</i> , 2003, 24, 256-271.	1.9	56
11	Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. <i>Clinical Trials</i> , 2007, 4, 218-234.	1.6	46
12	The use of subjective rankings in clinical trials with an application to cardiovascular disease. <i>Statistics in Medicine</i> , 1992, 11, 427-437.	1.6	41
13	Liability issues for data monitoring committee members. <i>Clinical Trials</i> , 2004, 1, 525-531.	1.6	37
14	Conduct of Clinical Trials in the Era of COVID-19. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2368-2378.	2.8	35
15	Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints. <i>European Heart Journal</i> , 2019, 40, 880-886.	2.2	34
16	Some practical problems in implementing randomization. <i>Clinical Trials</i> , 2010, 7, 235-245.	1.6	25
17	On changing a long-term clinical trial midstream. <i>Statistics in Medicine</i> , 2002, 21, 2789-2795.	1.6	22
18	Intercept studies, clinical trials, and cluster experiments: To whom can we extrapolate?. <i>Contemporary Clinical Trials</i> , 1994, 15, 24-29.	1.9	21

#	ARTICLE	IF	CITATIONS
19	Reports to Independent Data Monitoring Committees: An Appeal for Clarity, Completeness, and Comprehensibility. Therapeutic Innovation and Regulatory Science, 2018, 52, 459-468.	1.6	18
20	Responsibilities of Data Monitoring Committees: Consensus Recommendations. Therapeutic Innovation and Regulatory Science, 2016, 50, 648-659.	1.6	10
21	On independent data monitoring committees in oncology clinical trials. Chinese Clinical Oncology, 2014, 3, 40.	1.2	7
22	Data monitoring committee interim reports: We must get there soon!. Clinical Trials, 2022, 19, 107-111.	1.6	5
23	Commentary on Randomization: The forgotten component of the randomized clinical trial. Statistics in Medicine, 2019, 38, 14-16.	1.6	3
24	Mantel unhyphenated. , 1999, 18, 3381-3388.		2
25	The Modern Randomized Clinical Trial: Is it Time to Sharpen a Blunt Instrument?. Statistical Communications in Infectious Diseases, 2019, 11, .	0.2	1
26	Commentary on Chirkova et al.: Some comments on "socialist pharmapolitics". Clinical Trials, 2021, 18, 277-278.	1.6	1
27	Comment on paper by Crowe et al. Clinical Trials, 2009, 6, 441-442.	1.6	0
28	Thoughts on A.B. Hill's Watson Lecture. Statistics in Medicine, 2021, 40, 55-57.	1.6	0